Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
Want to see ABVX full AI Analyst Report?
Top Page
Abivax SA Sponsored ADR
(NASDAQ:ABVX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$101.00
▼(-15.95% Downside)
Action:Reiterated
Date:06/05/26
The score is held down primarily by weak financial performance (zero revenue, widening losses, and substantial cash burn) and bearish technicals (below major moving averages with negative MACD). A strengthened balance sheet and low leverage provide some support, but profitability and cash consumption remain the dominant risks.
Positive Factors
Strong cash runway
A cash balance near €492M and an indicated runway into Q4 2027 materially lowers near-term financing risk and supports completion of pivotal Phase 3 work and commercialization prep. This funding buffer gives management time to reach catalytic readouts without immediate dilution pressure.
Negative Factors
No current product revenue
Zero revenue underscores that Abivax remains fully pre-commercial and depends entirely on development financing. Without commercial sales, the company must continually access capital markets or partners to bridge development to launch, exposing shareholders to dilution and execution risk if milestones slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
A cash balance near €492M and an indicated runway into Q4 2027 materially lowers near-term financing risk and supports completion of pivotal Phase 3 work and commercialization prep. This funding buffer gives management time to reach catalytic readouts without immediate dilution pressure.
Read all positive factors
Abivax SA Sponsored ADR (ABVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.90B
Dividend YieldN/A
Average Volume (3M)2.11M
Price to Earnings (P/E)―
Beta (1Y)2.63
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees69
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.69
Shares Outstanding79,770,190
10 Day Avg. Volume4,395,657
30 Day Avg. Volume2,112,068
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-28.44
Forecast
1Y Price Target
$143.17Price Target Upside19.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.96
Revenue Forecast (FY)$81.52M
Abivax SA Sponsored ADR Business Overview & Revenue Model
Company Description
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX...
How the Company Makes Money
null...
Abivax SA Sponsored ADR Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -50.76M | -45.52M |
| EBITDA | -300.70M | -162.71M | -133.21M | -53.31M | -38.59M |
| Net Income | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | |||||
| Total Assets | 584.09M | 205.23M | 327.06M | 75.54M | 109.23M |
| Cash, Cash Equivalents and Short-Term Investments | 530.16M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 32.08M | 97.36M | 58.04M | 39.16M | 51.65M |
| Total Liabilities | 129.08M | 164.64M | 131.05M | 68.36M | 83.30M |
| Stockholders Equity | 455.01M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | |||||
| Free Cash Flow | -155.83M | -154.72M | -100.28M | -54.26M | -47.30M |
| Operating Cash Flow | -155.69M | -154.07M | -100.01M | -53.94M | -45.66M |
| Investing Cash Flow | -13.18M | 15.76M | -10.49M | -12.03M | -1.46M |
| Financing Cash Flow | 531.94M | 28.21M | 340.57M | 32.21M | 78.51M |
Abivax SA Sponsored ADR Technical Analysis
Negative
120.16
Price Trends
116.48
Negative
117.20
Negative
110.42
Negative
Market Momentum
-5.31
Positive
41.85
Neutral
47.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Negative. The current price of 120.16 is above the 20-day moving average (MA) of 113.50, above the 50-day MA of 116.48, and above the 200-day MA of 110.42, indicating a bearish trend. The MACD of -5.31 indicates Positive momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of 47.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABVX.
Abivax SA Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $6.22B | ― | -24.91% | ― | 56.70% | -13.77% | |
59 Neutral | $9.74B | ― | -42.78% | ― | ― | -37.66% | |
54 Neutral | $199.62M | -3.09 | -29.67% | ― | ― | ― | |
52 Neutral | $8.52B | ― | 139.66% | ― | 450.60% | -28.90% | |
52 Neutral | $6.03B | ― | -203.25% | ― | 58.67% | -11.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $7.90B | ― | -165.19% | ― | ― | ― |
* Healthcare Sector Average
ABVX
Abivax SA Sponsored ADR
98.03
90.61
1221.16%
CYTK
Cytokinetics
67.07
33.96
102.57%
RYTM
Rhythm Pharmaceuticals
85.71
20.87
32.19%
LEGN
Legend Biotech
34.86
-1.73
-4.73%
RNA
Atrium Therapeutics, Inc.
11.67
-3.08
-20.88%
NUVL
Nuvalent
123.35
46.44
60.38%
Abivax SA Sponsored ADR Corporate Events
Abivax Posts Q1 2026 Results and Shows Durable Seven-Year Obefazimod Remission in Ulcerative Colitis
May 22, 2026
On May 22, 2026, Abivax reported its first-quarter 2026 results and long-term data from Study 108, an open-label extension trial of obefazimod in moderately to severely active ulcerative colitis. After two to four years on 50 mg, 130 patients de-e...
Abivax Shareholders Approve 2025 Accounts and Governance Resolutions at May 11 AGM
May 20, 2026
Abivax SA, a clinical-stage biotechnology company focused on immune-regulating therapies for chronic inflammatory diseases, operates from France and the U.S. with a primary emphasis on its Phase 3 lead candidate obefazimod (ABX464) for moderately ...
Abivax Buys Back $90 Million in Royalties via $45 Million ADS Offering, Keeps Cash Runway to Q4 2027
May 7, 2026
On May 4, 2026, Abivax SA agreed to repurchase all outstanding royalty certificates issued in 2022 from existing holders for a total of $90 million, paying $45 million in cash and $45 million via an interest-free vendor’s loan that will be c...
Abivax Publishes Preparatory Documents for May 11, 2026 General Meeting
Apr 20, 2026
Abivax SA, a clinical-stage biotechnology company specializing in immune-regulating therapies for chronic inflammatory diseases, is advancing obefazimod (ABX464) through Phase 3 trials in moderately to severely active ulcerative colitis. The compa...
Abivax Posts 2025 Results, Confirms Phase 3 Ulcerative Colitis Timeline and Expands Leadership Team
Mar 23, 2026
Abivax reported its audited full-year 2025 financial results on March 23, 2026, highlighting a July 28, 2025 U.S. offering that raised about €597.2 million and a year-end cash, cash equivalents and short-term investment balance of €530...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.